ATE471383T1 - Promotoren zur expression in modifiziertem vaccinia virus ankara - Google Patents

Promotoren zur expression in modifiziertem vaccinia virus ankara

Info

Publication number
ATE471383T1
ATE471383T1 AT07014231T AT07014231T ATE471383T1 AT E471383 T1 ATE471383 T1 AT E471383T1 AT 07014231 T AT07014231 T AT 07014231T AT 07014231 T AT07014231 T AT 07014231T AT E471383 T1 ATE471383 T1 AT E471383T1
Authority
AT
Austria
Prior art keywords
expression
vaccinia virus
promotors
virus ankara
modified vaccinia
Prior art date
Application number
AT07014231T
Other languages
English (en)
Inventor
Sonja Leyrer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of ATE471383T1 publication Critical patent/ATE471383T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • A61K39/285Vaccinia virus or variola virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT07014231T 2003-11-24 2004-01-17 Promotoren zur expression in modifiziertem vaccinia virus ankara ATE471383T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200301730 2003-11-24

Publications (1)

Publication Number Publication Date
ATE471383T1 true ATE471383T1 (de) 2010-07-15

Family

ID=34442836

Family Applications (4)

Application Number Title Priority Date Filing Date
AT07014231T ATE471383T1 (de) 2003-11-24 2004-01-17 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT04000943T ATE377088T1 (de) 2003-11-24 2004-01-17 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT08008470T ATE504654T1 (de) 2003-11-24 2004-10-27 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT04790902T ATE420191T1 (de) 2003-11-24 2004-10-27 Promotoren zur expression im modifizierten vacciniavirus ankara

Family Applications After (3)

Application Number Title Priority Date Filing Date
AT04000943T ATE377088T1 (de) 2003-11-24 2004-01-17 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT08008470T ATE504654T1 (de) 2003-11-24 2004-10-27 Promotoren zur expression in modifiziertem vaccinia virus ankara
AT04790902T ATE420191T1 (de) 2003-11-24 2004-10-27 Promotoren zur expression im modifizierten vacciniavirus ankara

Country Status (18)

Country Link
US (3) US7816508B2 (de)
EP (4) EP1845164B1 (de)
JP (2) JP2007512009A (de)
KR (1) KR20060109873A (de)
CN (1) CN1898390A (de)
AT (4) ATE471383T1 (de)
AU (1) AU2004295382A1 (de)
BR (1) BRPI0416916A (de)
CA (1) CA2546680A1 (de)
DE (4) DE602004027767D1 (de)
DK (3) DK1536015T3 (de)
EA (1) EA012846B1 (de)
IL (4) IL174653A0 (de)
NO (1) NO20062948L (de)
NZ (1) NZ547405A (de)
SG (2) SG169325A1 (de)
UA (1) UA90098C2 (de)
WO (1) WO2005054484A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL212047B1 (pl) * 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
EP1845164B1 (de) * 2003-11-24 2010-06-16 Bavarian Nordic A/S Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
EP2042604A1 (de) * 2007-09-26 2009-04-01 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) VV-Promotergesteuerte Überexpression von rekombinanten Antigenen
JP2012509678A (ja) * 2008-11-27 2012-04-26 バヴァリアン・ノルディック・アクティーゼルスカブ 組換えウイルス発現のためのプロモーター
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
WO2012048817A2 (en) 2010-10-15 2012-04-19 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara influenza vaccine
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106754921A (zh) * 2016-12-12 2017-05-31 孙浩 哺乳动物细胞表达启动子及其制造和使用方法
EP3621646A4 (de) * 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center Mutanten des vaccinia-virus für die krebsimmuntherapie
EP4680277A1 (de) 2023-03-17 2026-01-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv-antigen-formulierung zur behandlung von hepatitis b
WO2025172435A1 (en) 2024-02-13 2025-08-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv antigen formulation for treating hepatitis b
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
CN1291012C (zh) 2000-03-14 2006-12-20 巴法里安诺迪克有限公司 修饰的安卡拉牛痘病毒(mva)的变株
PL212047B1 (pl) * 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
JP4554887B2 (ja) * 2001-03-08 2010-09-29 アメリカ合衆国 改変HIVエンベロープ、gag、およびpol遺伝子を発現するMVA
BR0310020A (pt) 2002-05-16 2005-02-15 Bavarian Nordic As Expressão de genes no vìrus da vacìnia modificado ancara por uso do promotor de ati de vacìnia
DE60336653D1 (de) * 2002-08-07 2011-05-19 Bavarian Nordic As Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
EP1845164B1 (de) * 2003-11-24 2010-06-16 Bavarian Nordic A/S Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara

Also Published As

Publication number Publication date
EP1845164B1 (de) 2010-06-16
DK1689872T3 (da) 2009-04-27
DK1536015T3 (da) 2008-02-18
EP1845164A2 (de) 2007-10-17
JP2011067219A (ja) 2011-04-07
IL199126A (en) 2010-12-30
US7816508B2 (en) 2010-10-19
DE602004018975D1 (de) 2009-02-26
IL199127A (en) 2010-12-30
JP2007512009A (ja) 2007-05-17
BRPI0416916A (pt) 2007-01-23
IL199128A (en) 2011-03-31
DK1845164T3 (da) 2010-09-20
DE602004009743T2 (de) 2008-08-28
EP1689872A1 (de) 2006-08-16
ATE377088T1 (de) 2007-11-15
DE602004032187D1 (de) 2011-05-19
EP1536015B1 (de) 2007-10-31
UA90098C2 (en) 2010-04-12
EP1845164A3 (de) 2008-03-19
EP1956094A1 (de) 2008-08-13
DE602004027767D1 (de) 2010-07-29
ATE504654T1 (de) 2011-04-15
EP1956094B1 (de) 2011-04-06
EP1689872B1 (de) 2009-01-07
ATE420191T1 (de) 2009-01-15
AU2004295382A1 (en) 2005-06-16
US20110008792A1 (en) 2011-01-13
DE602004009743D1 (de) 2007-12-13
NO20062948L (no) 2006-08-23
KR20060109873A (ko) 2006-10-23
US20080112971A1 (en) 2008-05-15
EP1536015A1 (de) 2005-06-01
SG169325A1 (en) 2011-03-30
IL174653A0 (en) 2006-08-20
EA200601043A1 (ru) 2006-10-27
CN1898390A (zh) 2007-01-17
CA2546680A1 (en) 2005-06-16
NZ547405A (en) 2008-06-30
SG142300A1 (en) 2008-05-28
WO2005054484A1 (en) 2005-06-16
US20110014242A1 (en) 2011-01-20
EA012846B1 (ru) 2009-12-30

Similar Documents

Publication Publication Date Title
IL199127A (en) Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters
DE60332355D1 (de) Hla-a24-restringiertes krebsantigenpeptid
NO20045480L (no) Intergeniske regioner som innskuddsseter i genomet til vacciniavirus ankara(MVA)
ATE490262T1 (de) Abschwächung der immunogenizität von fusionsproteinen
UA82998C2 (ru) Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
MXPA05005549A (es) Virus recombinante de viruela que comprende al menos dos promotores ati de viruela de vaca.
ATE547519T1 (de) Gerinnungsfaktor-vii-polypeptide
IL164179A0 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
MX2022015489A (es) Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
CY1109244T1 (el) Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου.
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
ATE404219T1 (de) Rekombinante poxvirus-calicivirus zusammensetzungen und anwendungen
BRPI0516576A (pt) vetores quiméricos
WO2003018756A3 (en) Methods for preparing purified prostaglandin e synthase
DE50312368D1 (de) Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria
WO2005001096A8 (en) Vaccines against sars
WO2005094415A3 (en) Recombinant vectors and methods for inducing an immune response
ATE547530T1 (de) Rekombinante vektoren auf der grundlage des modifizierten vacciniavirus ankara (mva) als impfstoffe gegen leishmaniase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1845164

Country of ref document: EP